Views: 1246 Downloads: 94

Razi Ghanavati Mohammadi , Elham Rajaei^*✉ , Alireza Ghanbaran , Seyed Ali Fatemi-Behbahani , Karim Mowla

1. Department of Internal Medicine, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Abstract

Inflammatory arthropathies (IAs) are a group of chronic autoimmune diseases that most commonly affect women of childbearing age. Etanercept is an anti-TNF drug that has been shown to be effective in treating IA patients; however, there is limited data on its safety in pregnant women, especially in Asian countries. This study aimed to evaluate the pregnancy and neonatal outcomes in pregnant patients with IA receiving etanercept. In the present retrospective study, the records of patients with IAs treated with etanercept at Golestan Hospital in Ahvaz during the years 2016-2020 were reviewed and the required information was extracted.

The records of 13 patients (52%) with spondylitis, spondyloarthritis (AS), and 12 patients (48%) with rheumatoid arthritis (RA) were reviewed. Twenty-one patients (84%) had no adverse delivery outcome and 4 patients (16%) had problems during delivery including terminal complication (1 case), abortion (1 case), premature rupture of the bladder (1 case), and pre-eclamptic complication (1 case). Twenty-four patients (96%) had no neonatal complications and 1 patient (4%) had neonatal Intrauterine Growth Restriction (IUGR) complication. In nine patients (36%), cesarean delivery was conducted and in 16 cases (64%), natural delivery was performed. The prevalence of cesarean section and pregnancy and neonatal outcomes were not significantly different according to the type of disease. Based on the results of the present study, it is not possible to make definitive conclusions about the safety of etanercept during pregnancy, and more studies with larger sample sizes are needed‎.

Keywords: Pregnancy, Neonatal, Outcome, Etanercept, Inflammatory arthropathy

Citation Formats: